Jubilant Pharmova Ltd (JUBLPHARMA) Q4FY26 Concall Summary - Mar-2026 Qtr
Performance Overview
- The company reported strong revenue growth of 19% YoY for the quarter, driven by performance in the Radiopharma, Allergy, CDMO Sterile Injectables, and Generics businesses.
- EBITDA for the quarter increased by 2% YoY, but the EBITDA margin contracted by 272 basis points to 15.7%, primarily due to a supply shortage of high-margin SPECT products in the Radiopharma segment and under-absorption of costs.
- The CDMO Sterile Injectables segment is showing significant momentum, with the new Line 3 at the Spokane facility onboarding over 10 products, including a major global oncology product, and is expected to reach peak revenue of USD 80-90 million one and a half to two years ahead of schedule.
- The Radiopharma business faces a temporary headwind in H1 FY27 due to the SPECT product supply shortage from the Montreal facility, which is expected to normalize in the second half of the year.
- The company is advancing its strategic capital expenditure projects, including Lines 4 and 5 at Spokane and Montreal respectively, and the PET radiopharmacy network, which are key to its long-term growth vision.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.